Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2018, Article ID 9616234, 5 pages
https://doi.org/10.1155/2018/9616234
Clinical Study

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

1Internal Medicine Department, Gastroenterology and Hepatology Unit, Ain Shams University, Cairo, Egypt
2Tropical Medicine Department, Ain Shams University, Cairo, Egypt
3Tropical Medicine & Infectious Diseases Department, Tanta University, Tanta, Egypt

Correspondence should be addressed to Sherief Abd-Elsalam; moc.oohay@laciport_firehs

Received 19 December 2017; Accepted 19 February 2018; Published 20 March 2018

Academic Editor: Daisuke Morioka

Copyright © 2018 Ossama Ashraf Ahmed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Gower, C. C. Estes, S. Hindman, K. Razavi-Shearer, and H. Razavi, “Global epidemiology and genotype distribution of the hepatitis C virus,” Journal of Hepatology, vol. 61, supplement 1, pp. S45–S57, 2014. View at Publisher · View at Google Scholar
  2. A. E. M. Aly Abd Elrazek, S. E. Bilasy, A. E. M. Elbanna, and A. E. A. Elsherif, “Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis,” Medicine (United States), vol. 93, no. 28, p. e204, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Elwan, A. Elfert, S. Abd-Elsalam et al., “Study of hepatic steatosis index in patients with chronic HCV infection,” International Journal of Current Microbiology and Applied Sciences, vol. 5, no. 5, pp. 266–279, 2016. View at Publisher · View at Google Scholar
  4. S. Abd-Elsalam, M. Sharaf-Eldin, S. Soliman, A. Elfert, R. Badawi, and Y. K. Ahmad, “Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice,” Archives of Virology, pp. 1–6, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. O. A. Ahmed, H. H. Kaisar, N. Hawash et al., “Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of egyptian patients with hepatitis C virus infection,” Infectious Disorders—Drug Targets, vol. 17, no. 2, pp. 95–100, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Bertino, A. Ardiri, M. Proiti et al., “Chronic hepatitis C: this and the new era of treatment,” World Journal of Hepatology, vol. 8, no. 2, pp. 92–106, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Banerjee and K. R. Reddy, “Review article: Safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy,” Alimentary Pharmacology & Therapeutics, vol. 43, no. 6, pp. 674–696, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Pol, A. Vallet-Pichard, and M. Corouge, “Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life,” Hepatic Medicine: Evidence and Research, vol. 8, pp. 21–26, 2016. View at Publisher · View at Google Scholar
  9. E. Hathorn and A. M. Elsharkawy, “Management of hepatitis C genotype 4 in the directly acting antivirals era,” BMJ Open Gastroenterology, vol. 3, no. 1, Article ID e000112, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-Torres et al., “Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection,” The New England Journal of Medicine, vol. 370, no. 15, pp. 1469–1469, 2014. View at Publisher · View at Google Scholar
  11. H. Fontaine, C. Hezode, F. Zoulim et al., “Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-monoinfected patients from the french observational cohort ANRS CO22 Hepather,” in Proceedings of the 50th Annual Meeting of European Association for the Study of the1 Liver, Vienna, Austria, April 2015. View at Publisher · View at Google Scholar
  12. H. Omar, W. El Akel, T. Elbaz et al., “Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt,” Alimentary Pharmacology & Therapeutics, vol. 47, no. 3, pp. 421–431, 2018. View at Publisher · View at Google Scholar
  13. M. A. Babatin, A. S. Alghamdi, A. Albenmousa et al., “Efficacy and safety of simeprevir or daclatasvir in combination with sofosbuvir for the treatment of hepatitis C genotype 4 infection,” Journal of Clinical Gastroenterology, Article ID 28767462, 2017. View at Publisher · View at Google Scholar
  14. R. Mehta, M. Kabrawala, S. Nandwani et al., “Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients with β-thalassemia major,” Journal of Clinical and Experimental Hepatology, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Elsharkawy, M. El-Raziky, W. El-Akel et al., “Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: lessons from the egyptian experience,” Journal of Hepatology, 2017. View at Publisher · View at Google Scholar